Nutramedic &Cosmetics
New Study Demonstrates Levagen+® Positively Impacts URTIs Gencor has announced the publication of its recent human clinical trial demonstrating its palmitoylethanolamide (PEA) ingredient, Levagen®+, to be a safe and effective supplement for upper respiratory tract infections (URTIs).
U
RTIs are caused by an infection of the muco sal lining of the upper airway and include coughing, sneezing, stuffy or runny nose, fe ver, and scratchy or sore throat. PEA is an endocan nabinoid-like bioactive signaling lipid that is part of the N-acylethanolamine (NAE) family. In the case of URTIs, there is an increase in inflammatory cytokine production. PEA has been shown to have potent an ti-inflammatory effects that impact the expression of cytokine released. The double-blind, randomized, placebo-controlled study, published in the journal Nu trients, investigated the effectiveness of Levagen+ on URTI incidence, duration, and severity over 12 weeks. Three hundred and ninety-eight participants bet ween 18 and 65 were allocated to the Levagen+ group or the placebo. The Levagen+ group con sumed 300mg twice daily, and the placebo group consumed 300mg twice daily of maltodextrin. All participants completed the SF-8 questionnaire to measure the health-related quality of life every four weeks. A total of 87 participants experienced at least one URTI during the study, with a total of 103 URTI episodes recorded. The results showed that the
total number of URTI episodes was significantly low er in the Levagen+ group when compared with the placebo group. There was also a significant differ ence in the severity of scratchy throats and report ed coughing between the two groups, demonstrat ing that Levagen+ is a safe and effective supple ment for URTIs. “We are thrilled with the outcomes of this study; along with a healthy diet and exercise, Levagen+ can be a strong ingredient to support immune health,” R.V. Venkatesh, Co-founder at Gencor. “We have sev eral published studies backing Levagen’s efficacy and will continue investigating this potent ingredi ent for improved health and wellbeing.” Levagen®+ is a bioavailable palmitoylethanolami de (PEA), a self-affirmed GRAS ingredient manufac tured in cGMP facilities, and has been clinically test ed to support joint health, sleep, recovery, and im munity. Levagen+ is applicable for dietary supple ments, food and beverages, and cosmeceuticals. www.levagenplus.com www.GencorPacific.com
41
